BeyondSpring (NASDAQ:BYSI) Stock Price Up 2.4% – What’s Next?

Shares of BeyondSpring Inc. (NASDAQ:BYSI) traded up 2.4% during mid-day trading on Tuesday . The company traded as high as $1.3399 and last traded at $1.30. 13,361 shares changed hands during mid-day trading, a decline of 50% from the average session volume of 26,595 shares. The stock had previously closed at $1.27.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d+)” rating on shares of BeyondSpring in a report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, BeyondSpring presently has a consensus rating of “Sell”.

BeyondSpring Trading Up 2.4%

The company’s fifty day simple moving average is $1.68 and its 200 day simple moving average is $1.82. The firm has a market capitalization of $52.43 million, a P/E ratio of -8.67 and a beta of 0.54.

Institutional Trading of BeyondSpring

A hedge fund recently raised its stake in BeyondSpring stock. Geode Capital Management LLC grew its position in shares of BeyondSpring Inc. (NASDAQ:BYSI) by 951.4% during the second quarter, according to its most recent filing with the SEC. The firm owned 256,212 shares of the company’s stock after acquiring an additional 231,844 shares during the period. Geode Capital Management LLC owned about 0.64% of BeyondSpring worth $603,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 40.29% of the company’s stock.

BeyondSpring Company Profile

BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.

The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.